Phase III Randomized Controlled Trial of eRAPID: eHealth Intervention During Chemotherapy

eRAPID is a system for patients to self-report symptoms during cancer treatment. This analysis (n=508) found it was associated with improved physical well-being at 6 and 12 weeks, but not 18 weeks (primary endpoint), and with better reported self-efficacy and health on EQ5D-VAS.

Journal of Clinical Oncology